NCT05905432 (PamTBVac) is a Phase 1 clinical trial of Vaccine AnAPN1 in Malaria, sponsored by Centre de Recherche Médicale de Lambaréné.

Who is sponsoring NCT05905432?

NCT05905432 is sponsored by Centre de Recherche Médicale de Lambaréné.

What drugs are being tested in NCT05905432?

Interventions in NCT05905432: Vaccine AnAPN1.

Is NCT05905432 still recruiting?

NCT05905432 is currently completed. Last updated 2 May 2025.

Last reviewed 2025-05-02 · How we verify

NCT05905432: PamTBVac

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pan-Malaria Transmission-Blocking Vaccine AnAPN1

Completed Phase 1 Last updated 2 May 2025

What this trial tests

Phase 1 trial testing Vaccine AnAPN1 in Malaria in 33 participants. Completed in 31 January 2025.

Timeline

11 September 2023

Primary endpoint
22 January 2025

31 January 2025

Quick facts

Lead sponsor	Centre de Recherche Médicale de Lambaréné
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	33
Start date	11 September 2023
Primary completion	22 January 2025
Estimated completion	31 January 2025
Sites	1 location across Gabon

Drugs / interventions tested

Vaccine AnAPN1 — full drug profile →

Conditions studied

Malaria — all drugs for Malaria →

Sponsor

Centre de Recherche Médicale de Lambaréné — full company profile →

Who can join

Adults 18 to 45, any sex, with Malaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Malaria is still responsible for more than 627,000 deaths each year, predominantly among children under 5 years old. Current reductions in deaths have stagnated, and additional setbacks for malaria control programs due to the Coronavirus Disease 2019 (COVID-19) pandemic are expected. To achieve malaria elimination and eradication a leverage concerted approaches to reduce clinical disease and prevent new infections is a must. The existing malaria controls tools including the a recombinant protein-based malaria vaccine (RTS,S ,(trade name MosquirixMosquirix )), a malaria vaccine currently undergoing implementation studies and endorsed by the World Health Organization on October 7, 2021, can reduce disease burden for patients but cannot ultimately support malaria elimination and eradication since their effect on malaria transmission is at most partial. Consequently, complementary interventions, such as transmission-blocking vaccines (TBVs) may prove to be a cost-effective intervention that can reduce on-going residual transmission and the cascade of new infections.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Vaccines and monoclonal antibodies: new tools for malaria control.
Miura K, Flores-Garcia Y, Long CA, Zavala F. · · 2024 · cited 24× · PMID 38656211 · DOI 10.1128/cmr.00071-23
A new landscape for malaria vaccine development.
Laurenson AJ, Laurens MB. · · 2024 · cited 6× · PMID 38935630 · DOI 10.1371/journal.ppat.1012309

Verify or expand the search:

Other recruiting trials for Malaria

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting

Other Centre de Recherche Médicale de Lambaréné trials

Trials by the same sponsor.

NCT07017803 — Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region · not yet recruiting
NCT05929157 — A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate · Phase 1, PHASE2 · unknown
NCT05130398 — Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon · Phase 1, PHASE2 · completed
NCT04847817 — Important Data on COVID-19 Profile in Africa · completed
NCT04505046 — Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections. · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05905432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre de Recherche Médicale de Lambaréné
Last refreshed: 2 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05905432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing